- Home
- TLRY vs AVDL Comparison
TLRY vs AVDL Comparison
Compare TLRY & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- AVDL
- Stock Information
- Founded
- TLRY N/A
- AVDL 2015
- Country
- TLRY Canada
- AVDL Ireland
- Employees
- TLRY N/A
- AVDL N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- AVDL Health Care
- Exchange
- TLRY Nasdaq
- AVDL Nasdaq
- Market Cap
- TLRY 871.2M
- AVDL 867.3M
- IPO Year
- TLRY 2018
- AVDL 1996
- Fundamental
- Price
- TLRY $0.95
- AVDL $8.41
- Analyst Decision
- TLRY Hold
- AVDL Strong Buy
- Analyst Count
- TLRY 3
- AVDL 7
- Target Price
- TLRY $1.88
- AVDL $18.86
- AVG Volume (30 Days)
- TLRY 51.2M
- AVDL 1.3M
- Earning Date
- TLRY 04-08-2025
- AVDL 03-03-2025
- Dividend Yield
- TLRY N/A
- AVDL N/A
- EPS Growth
- TLRY N/A
- AVDL N/A
- EPS
- TLRY N/A
- AVDL N/A
- Revenue
- TLRY $829,216,000.00
- AVDL $138,160,000.00
- Revenue This Year
- TLRY $15.63
- AVDL $515.49
- Revenue Next Year
- TLRY $5.63
- AVDL $48.85
- P/E Ratio
- TLRY N/A
- AVDL N/A
- Revenue Growth
- TLRY 18.38
- AVDL 1523.50
- 52 Week Low
- TLRY $0.83
- AVDL $7.39
- 52 Week High
- TLRY $2.97
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- TLRY 40.67
- AVDL 45.85
- Support Level
- TLRY $0.97
- AVDL $8.27
- Resistance Level
- TLRY $1.20
- AVDL $9.34
- Average True Range (ATR)
- TLRY 0.08
- AVDL 0.44
- MACD
- TLRY -0.00
- AVDL 0.09
- Stochastic Oscillator
- TLRY 33.72
- AVDL 43.29
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.